On June 19, Twist Bioscience rose 5.62% in regular trading, trading at $87.435/share, with turnover of $131 million, extending its recent strong momentum.

On the news front, Canaccord Genuity issued a buy rating on Twist Bioscience with a target price of $90, significantly above the analyst consensus target price of $73.12 according to FactSet. The elevated target price has provided sustained upward pressure on the stock over recent sessions, with shares climbing from approximately $80 on June 15 to current levels, representing a cumulative gain of roughly 9% over the period.

Twist Bioscience is a synthetic biology platform company that develops silicon-based DNA synthesis technology, combining proprietary software with scalable commercial infrastructure to serve healthcare, food and agriculture, industrial chemicals, and data storage sectors. The company reported its most recent quarterly earnings on May 4, posting an EPS of -$0.62.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)